CASTEL SAN PIETRO, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Medacta International, the privately held family-owned global leader in the design of innovative joint replacement and spine surgery products, will highlight its newest surgical innovations at this week’s American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, held March 1-5 in Orlando, Florida at the Orange County Convention Center. As the industry’s premier event, the AAOS Annual Meeting convenes the world’s top orthopaedic surgeons, manufacturers and academics to discover the latest research, developments and products across the orthopaedic space. At Booth #753 Medacta will showcase its latest surgical innovations, including its GMK® Efficiency Single Use Knee Instruments and Mpact Dual Mobility Acetabular System, and will provide an update on its pioneering MySpine Patient-Matched Technology.
“The practice of orthopaedic surgery is constantly evolving, and Medacta stands ready to equip surgeons with innovative, effective tools for in-hospital and ambulatory surgery centers alike,” said Francesco Siccardi, executive vice president of Medacta International. “At this year’s meeting, we’ll provide an update on our GMK Efficiency Single Use Instruments for Knee Replacement, which have the potential to simplify the surgical procedure and provide benefits to the patient and facility while remaining carbon neutral. We will also showcase for the first time the Mpact Dual Mobility System for total hip replacement, which is built upon 40 years of clinical heritage and has been designed to provide unmatched stability and an exceptionally high range of motion, while potentially lowering dislocation rates. Our award-winning MySpine will also be on display as the first product available in the U.S. to produce tailor-made patient-matched guides for the spine vertebrae using proprietary CT scan algorithms and sophisticated 3D medical printing technology.”
Medacta products at this year’s AAOS Annual Meeting include:
GMK® Efficiency Single Use Instruments for Knee Replacement: Innovation That Delivers
GMK® Efficiency Single Use Instruments are a complete single-use instrumentation solution used to implant the GMK Primary or GMK Sphere in a total knee replacement (TKR) procedure, and are the first in a line of planned single-use instrumentation solutions that Medacta will introduce into the market in 2016. The number of total knee replacements is growing significantly, with the number of primary TKRs expected to reach 3.48 million annually by 2030, from 550,000 in 2008.1 All this is occurring at a time of economic downturn and financial constraints, resulting in a decrease of allocation of healthcare resources used by patients.
Delivered sterile and ready for use, the GMK Efficiency platform is designed to improve hospital and ambulatory surgery center (ASC) efficiency and allow for significant cost savings by decreasing tray management time and costs, while remaining carbon neutral. The platform optimizes the management of instrumentation within the operating room and provides substantial benefits to the patient and hospital or ASC by simplifying and streamlining the surgical procedure. The GMK Efficiency system also has the potential to decrease the risk of infection – especially important considering the obvious impact on the patient and high costs associated for a single site infection on the hospital.
The GMK Efficiency system is a phased launch, and is available now in combination with MyKnee Patient-Matched Technology implementations utilizing the Medacta GMK Primary and GMK® Sphere Knee products. The GMK Sphere implant itself delivers maximum functional stability to a replaced knee, with the goal of increasing total knee replacement patient satisfaction and decreasing post-operative knee pain. The GMK Sphere implant was developed after three years of pre-launch clinical evaluation and has seen more than 5,000 successful implants to date.
For more information on GMK Efficiency Single Use Instrument, visit: https://www.medacta.com/en/usa/medical-professionals/products/knee/gmk-efficiency/gmk-efficiency.
Mpact Dual Mobility System: Providing Unmatched Stability
Medacta currently holds 29 percent share of the U.S. dual mobility market with its Versafitcup Dual Mobility System and AMIStem, according to Orthopedics Network News. The Mpact Dual Mobility System will be added to the company’s robust dual mobility offerings, complementing the Versafitcup System, which serves as an alternative to ceramic-on-ceramic and metal-on-metal Large Heads for hip replacement. Mpact joins the ranks as a double mobility press fit cup, designed to enhance and provide stability after a total hip replacement procedure, with the potential to reduce dislocations and readmission rates. The device’s increased head-to-neck ratio provides a high range of motion, while the increased head diameter may reduce the risk of dislocation. The inclusion of Medacta’s MectaGrip coating, a plasma-sprayed titanium coating, enhances initial fixation due to its high coefficient of friction and long-term stability, and gives surgeons additional options for biological fixation.
A proven concept conceived from 40 years of clinical heritage, the Mpact Dual Mobility System is designed from original concepts described by Professor Gilles Bousquet, originator of the double mobility concept, with surgeons trained and schooled through the University of Saint-Etienne in France, the cradle of dual mobility technology. The device is compatible with Medacta’s Anterior Minimally Invasive Surgery (AMIS) Technique for hip replacement, which is associated with significant positive patient outcomes and encompasses an entire system of tools and educational resources Medacta has developed to support surgeons transitioning to this approach.
MySpine Patient-Matched Technology: Pioneering 3D-Printed Patient-Matched Guides for Spine
Medacta will also review key aspects of its award-winning MySpine Patient-Matched Technology. Using the company’s proven 3D-reconstruction and rapid 3D-printing technologies, MySpine offers customized patient-matched surgical guides intended to support spinal surgeons during the most complex deformity cases. Having received 510(k) clearance by the U.S. Food & Drug Administration (FDA) in May 2014, MySpine is the first product available in the U.S. to produce tailor-made patient-matched guides for the spine vertebrae utilizing proprietary CT scan algorithms and sophisticated 3D medical printing technology. The first surgeries using MySpine Patient-Matched Technology in the U.S. were completed in November 2015 and were shown to provide a high level of precision and accuracy, thus reducing overall time of the procedure and helping the surgeon to deliver more efficient care to the multiple patients he sees each day with challenging spinal cases.
Looking Forward: Continued Flexibility for Surgeons and Patients
The U.S. market specifically is moving toward more outpatient care, with recent research suggesting outpatient surgical volume in hospitals alone could increase by around 8-16 percent annually between 2014 and 2021, compared to annual growth rates of 1-3 percent in the previous decade.2 In parallel, growth in the number of Medicare-certified ambulatory surgery centers was 12 percent between 2007 and 2012.
Maintaining its commitment to meet surgeons’ and its markets’ growing needs, Medacta announced the Propel Same Day Surgery Initiative, an all-inclusive program that incorporates its orthopaedic expertise, commitment to surgeon education, and world-class products and services to support both outpatient and same-day surgery. The Initiative will include an introduction to Medacta’s products that are suitable for same-day surgery and outpatient care, including: its AMIS Program for total hip replacement, MyKnee and MySpine Patient-Matched technologies, and GMK Efficiency Single Use Instrumentation; a visit to a Learning Center to learn more about same-day spine and joint arthroplasty; and a visit to a Reference Center to experience the process a patient goes through at a same-day surgery facility firsthand, with experienced orthopaedic surgeons as proctors to mentor throughout the process.
“These newest innovations and developments further drive home Medacta’s commitment to sustainability and intelligently designed products and programs that make it easier for patients to rehabilitate faster, and for surgeons, hospitals and ASCs to more efficiently do their jobs,” Siccardi continued. “With our new products focused on sterilization, stability, and flexibility, Medacta is uniquely positioned to make outpatient joint replacement a reality, especially in the non-hospital setting. We are looking forward to an eventful year as we continue to meet these needs.”
About Medacta® International
Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a holistic approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit: https://www.medacta.com.
References:
1. Int. J. Clin. Rheumatol. (2010) 5 (5), 565-579
2. Munnich, E.L., and Parente, S.T. (2014, May). Procedures take less time at ambulatory surgery centers, keeping costs down and ability to meet demand up. Health Affairs. 33(5), 764-769
